Methods of treatment of malignancies

A method of treating a solid tumor in a subject comprising administering to the subject a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5 -triazin-2-yl)amino]propan-2-ol having the following formula:

• or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1), wherein the solid tumor is characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of FLT3.

A method of treating a hematological malignancy in a subject comprising administering to the subject a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:

• or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1) in combination with a FLT3 inhibitor, wherein the hematological malignancy is a malignancy characterized by the presence of a mutant allele of IDH2 and a mutant allele of FLT3.

A method of treating a solid tumor in a subject comprising administering to the subject a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:

• or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1) in combination with a FLT3 inhibitor, wherein the solid tumor is characterized by the presence of a mutant allele of IDH2 and a mutant allele of FLT3.

A method of identifying a cancer subject suitable for treatment with an IDH2 inhibitor, comprising:

• (a) obtaining a biological sample from a subject having cancer;
• (b) screening the biological sample for a mutant allele of IDH2 and a mutant allele of FLT3;
• and (c) if the cancer is characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of FLT3, identifying the subject as a cancer subject suitable for treatment with an IDH2 inhibitor.

A method of identifying a cancer subject suitable for treatment with a combination of an IDH2 inhibitor and a FLT3 inhibitor, comprising:

• (a) obtaining a biological sample from a subject having cancer;
• (b) screening the biological sample for a mutant allele of IDH2 and a mutant allele of FLT3;
• and (c) if cancer is characterized by the presence of a mutant allele of IDH2 and a mutant allele of FLT3, identifying the subject as a cancer subject suitable for treatment with a combination therapy with an IDH2 inhibitor and a FLT3 inhibitor.